APICES acknowledged for its remarkable role in LOADH Study

We are proud to announce that APICES has been acknowledged for its ongoing collaboration in the LOADH study, an Observational prospective study in Lung Cancer (NSCLC). This acknowledgement was highlighted in the Journal of Cancer Research and Clinical Oncology 2025.

APICES has contributed extensively to critical aspects throughout the trial, including start-up, coordination, project management, monitoring, medical monitoring, pharmacovigilance, data management, biostatistics, and medical writing activities.

This acknowledgment is a great motivation for the entire APICES team to continue the commitment we bring to every project we collaborate on. We sincerely thank Astrazeneca Spain and Dra. Irene Mangues-Bafalluy for giving us the opportunity to support the study as CRO and for including us acknowledgments. We also congratulate them and all investigators and patients on the LOADH Study progress and results.

The LOADH study aims to evaluate adherence to oral antineoplastic therapy (OAT) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and its potential relationship with several clinical outcomes.

For further information about the LOADH Study, please visit: LOADH STUDY